Trovafloxacin-Associated Leukopenia

Mitropoulos, Fotios; Angood, Peter B.; Rabinovici, Reuven

doi:10.1345/aph.10066

Cited by 13 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various drugs like fluroquinolones group, such as ofloxacin, ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin, antimalarials, penicillins, sulfonamides, antithyroid medications, anticonvulsants, anticancer drugs, and vancomycin are implicated to cause neutropenia, pancytopenia, bone marrow suppression, and myeloid maturation arrest. 7,8 Levamisole, another antihelminthic and immunomodulator, also suppresses bone marrow and induces neutropenia. Cyclic or periodic neutropenia may be related to congenital diseases or related to toxic exposure.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vancomycin-Induced Maturation Arrest with Reactive Promyelocyte Proliferation: A Diagnostic and Therapeutic Challenge

2022

View full text Add to dashboard Cite

Drug-induced leukopenia is a diagnostic and therapeutic challenge. A detailed clinical history is a must to come to a right diagnosis. Certain drugs are known to cause bone marrow suppression, leukopenia, myeloid maturation arrest, and reactive promyelocyte proliferation. Here, we report an unusual case of vancomycin-induced maturation arrest with marked promyelocyte proliferation in a 47-year-old male patient who was being treated for novel coronavirus disease 2019 (COVID-19) infection. Most times, this reactive promyelocyte proliferation is confused with neoplastic promyelocytes, leading to incorrect diagnosis and management.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Vancomycin-Induced Maturation Arrest with Reactive Promyelocyte Proliferation: A Diagnostic and Therapeutic Challenge

2022

View full text Add to dashboard Cite

show abstract

“…Other fluoroquinolones that have been reported to cause neutropenia include ciprofloxacin, norfloxacin, pefloxacin, ofloxacin, and trovafloxacin. 8–15 The incidence of leukopenia associated with ciprofloxacin therapy was reported to be zero to 0.247% (7/2829). 13–15 A review summarizing the pooled data that included 15,641 patients treated with ofloxacin and 1181 treated with pefloxacin disclosed that the incidence was 0.5% and 0.25%, respectively (Table 2).…”

Section: Discussionmentioning

confidence: 99%

Moxifloxacin-Associated Neutropenia in a Cirrhotic Elderly Woman with Lower Extremity Cellulitis

Chang

Lee²,

Lee³

et al. 2008

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…This association was further supported by the exclusion of other potential causes for this adverse effect. Healthcare personnel should be aware of this possible adverse reaction in patients treated with trovafloxacin [54].…”

Section: Leucopeniamentioning

confidence: 99%

Structural Development, Haematological Immunological and Pharmacological Effects of Quinolones

Chide

Orisakwe²

2007

PRI

View full text Add to dashboard Cite

The interest of the medical community in quinolones has not decreased despite more than ten years of continuous and growing use of these agents. The constant need for new anti microbials has produced a variety of newer quinolones termed as I, II, III, and IV generation. Nalidixic acid and other early quinolones had limited use due to poor pharmacokinetics, relatively narrow antimicrobial spectrum of activity, and frequent adverse effects. Extensive pharmacologic and clinical development of quinolone antimicrobial agents has resulted in improved antimicrobial activity, pharmacokinetic features, toxicity, and drug-drug interaction profiles. These attributes, coupled with their expanded spectrum and the immune enhancing phenomena of quinolones with a cyclopropyl moiety at position 1 of the quinolone ring suggest that the newer fluoroquinolones are so far the most ideal agents for the empirical treatment of many common infections. The above has made it desirable to review the status of these agents as revealed in published literature. The thrust of this review is on the structural development, pharmacological, haematological and immunological effects of quinolones. Recent patents filed are also discussed.

show abstract

Trovafloxacin-Associated Leukopenia

Abstract: Leukopenia is a well-recognized adverse effect of several drugs. We report a case of trovafloxacin-associated leukopenia during treatment of a trauma patient. Healthcare personnel should be aware of this possible adverse reaction in patients treated with trovafloxacin.

Cited by 13 publications

References 14 publications

Vancomycin-Induced Maturation Arrest with Reactive Promyelocyte Proliferation: A Diagnostic and Therapeutic Challenge

Vancomycin-Induced Maturation Arrest with Reactive Promyelocyte Proliferation: A Diagnostic and Therapeutic Challenge

Moxifloxacin-Associated Neutropenia in a Cirrhotic Elderly Woman with Lower Extremity Cellulitis

Structural Development, Haematological Immunological and Pharmacological Effects of Quinolones

Contact Info

Product

Resources

About